Startseite>>Signaling Pathways>> Others>> Nucleic Acid Turnover/Signaling>>6-Aminophenanthridine

6-Aminophenanthridine (Synonyms: 6AP)

Katalog-Nr.GC40479

6-Aminophenanthridin hemmt die ProteinfaltungsaktivitÄt des Ribosoms (PFAR).

Products are for research use only. Not for human use. We do not sell to patients.

6-Aminophenanthridine Chemische Struktur

Cas No.: 832-68-8

Größe Preis Lagerbestand Menge
1mg
43,00 $
Auf Lager
5mg
150,00 $
Auf Lager
10mg
280,00 $
Auf Lager
25mg
589,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

6-Aminophenanthridine is an antiprion agent. It inhibits prion formation in yeast- and mammalian-based screening assays when used alone and, to a greater extent, when used in combination with the α2-adrenergic receptor agonist guanabenz . 6-Aminophenanthridine (300 µM) inhibits protein folding activity of the ribosome (PFAR) by directly competing with protein substrates for the active site and decreases the yield of refolded protein without affecting the refolding rate. It prevents progressive wing position defects in a Drosophila model of oculopharyngeal muscular dystrophy (OPMD) when larvae are raised on medium containing doses ranging from 300 to 400 µM and in adults following dietary administration of 1-3 mM doses. 6-Aminophenanthridine also reduces muscle degeneration and decreases the number of nuclear inclusions in thoracic muscle in a Drosophila model of OPMD.

Bewertungen

Review for 6-Aminophenanthridine

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 6-Aminophenanthridine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.